

## **PRESS RELEASE**

03 September 2025 09:00:00 CEST

## **AcouSort AB changes Certified Adviser to Tapper Partners AB**

AcouSort AB announces today that the company is changing its Certified Adviser to Tapper Partners AB.

AcouSort AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser. Tapper Partners AB will assume the role of Certified Adviser on September 5, 2025. Until then, DNB Carnegie Investment Bank AB will continue to act as the company's Certified Adviser.

## FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

## **ABOUT ACOUSORT**

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is DNB Carnegie Investment Bank AB.